Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Cash from Operations (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Cash from Operations for 15 consecutive years, with 5967000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 41.88% to 5967000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 37923000.0 through Dec 2025, down 0.61% year-over-year, with the annual reading at 37923000.0 for FY2025, 0.61% down from the prior year.
  • Cash from Operations hit 5967000.0 in Q4 2025 for Cardiff Oncology, up from 10834000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 4301000.0 in Q2 2021 to a low of 12794000.0 in Q1 2025.
  • Historically, Cash from Operations has averaged 8168150.0 across 5 years, with a median of 7848500.0 in 2023.
  • Biggest five-year swings in Cash from Operations: plummeted 74.39% in 2021 and later soared 41.88% in 2025.
  • Year by year, Cash from Operations stood at 7390000.0 in 2021, then decreased by 27.06% to 9390000.0 in 2022, then grew by 23.97% to 7139000.0 in 2023, then plummeted by 43.82% to 10267000.0 in 2024, then skyrocketed by 41.88% to 5967000.0 in 2025.
  • Business Quant data shows Cash from Operations for CRDF at 5967000.0 in Q4 2025, 10834000.0 in Q3 2025, and 8328000.0 in Q2 2025.